Penny Mohr, MA, senior program officer for improving healthcare systems at the Patient-Centered Outcomes Research Institute, discusses comparative effectiveness research, healthcare disparities, and patient-centered care at the 20th annual international meeting of ISPOR.
Penny Mohr, MA, senior program officer for improving healthcare systems at the Patient-Centered Outcomes Research Institute (PCORI), discusses comparative effectiveness research, healthcare disparities, and patient-centered care at the 20th annual international meeting of ISPOR.
What is the importance of comparative effectiveness research on patient-centered care?
I think it’s very essential for patient-centered care because comparative effectiveness research by definition is really to look at choices that are appropriate to patients. And so when you’re looking at those choices and doing research on which item works better than the other, the patients are making those choices and the research really needs to inform those choices. So it should relate directly back to patient-centered care.
What work is PCORI currently doing to address healthcare disparities?
We have invested over $150 million in addressing disparities research and it is one of our 5 major priorities within PCORI when the initial plan of priorities was identified by the organization. Addressing disparities is built directly into the mission for the organization.
There are several population groups that we are focusing that are high-priority population groups for addressing disparities. And those include the low-income population, people who don’t speak English, the LGBT population, racial and ethnic minorities, and rural populations. Those are the major populations that we’re focusing on. We have also several major initiatives in this area looking at reducing obesity and also reducing hypertension.
What are some of the challenges of addressing and closing the healthcare disparities gap?
First of all, the research is very different than a lot of comparative effectiveness research. It involved multi-level, multi-component, complex interventions, and you have to think a lot of what are the barriers and facilitators, and it’s quite complex to think through that in order to get an intervention that works.
In addition you want to be looking at of different subpopulations as well within the groups. For instance, if you’re looking at the Hispanic population, there are a few levels of differences and how you will potentially approach the barriers that they face.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More